PAR 1.92% 25.5¢ paradigm biopharmaceuticals limited..

Ann: Type D Response Submitted and Received by the US FDA, page-18

  1. 567 Posts.
    lightbulb Created with Sketch. 107
    The response package to the US FDA has been submitted as directed by the Agency,
    through a request for review pathway. The request for review pathway does not have
    strict Prescription Drug User Fee Act (PDUFA) Agency response timelines, although
    feedback is typically received within three months.

    Looks like they are not bound by usual timelines @bobsee. This makes FDA response very unpredictable.

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
25.5¢
Change
-0.005(1.92%)
Mkt cap ! $89.19M
Open High Low Value Volume
27.0¢ 27.0¢ 25.5¢ $261.4K 990.7K

Buyers (Bids)

No. Vol. Price($)
1 9999 25.5¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 9445 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.